The use of Botulinum Toxin in dentristy The use of Botulinum Toxin in dentristy

Abstract

Clostridium botulinum is an anaerobic bacter, which produces until
eight types of toxins. The botulinum toxin A (BTX-A) is the most potent
among then, largely used in clinical procedures and approved for
several therapeutic instances. The Allergan Inc. company was the first to
produce BTX-A commercially called as “Botox®”. The therapeutic use
of BOTOX® is approved by ANVISA in Brazil since 2000, followed by
Food and Drug Administrartion in 2002. In Brazil, the Federal Council
of Dentistry recognizes BOTOX® by 198/2019 law and its utilization
in procedures such as facial reconcilement; or in therapeutics such
as bruxism, hypertrophy of chew muscles, temporomandibular joint
dysfunction, sialorrhea, asymmetry smile, and gingival profusion. Despite
its temporal use, the results are very interesting. BTX-A side effects are
considered for uses in miastenia gravis and Lambert-Eaton Syndrome,
which has, in common, a reduced acetylcholine release in synapses. Thus,
the aim of this work was to review the main BTX-A uses in dentistry area,
once its use has growing largely in aesthetics and in dentistry disorders.
Herein, we report the low risk in the use of BTX-A, with several interesting
benefits on dentistry areas, improving the quality of life and the selfesteem